23082-45-3

Upstream product

• 51-36-5 3,5-dichlorobenzoic acid 
• 2789-92-6 3,5-dichloroantranilic acid 
• 7697-37-2 nitric acid 
• 10203-08-4 3,5-dichlorobenzaldehyde 
• 118665-00-2 2,4-dichloro-6-methylnitrobenzene 
• 59178-12-0 3,5-dichloro-2-nitrobenzaldehyde 

Downstream Products

• 2789-92-6 3,5-dichloroantranilic acid 
• 229342-55-6 N-(5-chloro-2-pyridinyl)-2-nitro-3,5-dichlorophenylcarboxamide 
• 42860-31-1 3,5-dichloro-2-iodobenzoyl chloride 
• 1185755-24-1 4-[(3,5-dichloro-2-iodo-benzoyl)-(4-methoxy-benzyl)-amino]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1267952-21-5 2,4-dichloro-6-hydroxymethylnitrobenzene 
• 1267952-23-7 2,4-dichloro-6-methoxymethylnitrobenzene 
• 569328-81-0 (5-chloro-3-methoxymethyl-2-nitrophenyl)(4,6-dimethoxypyrimidin-2-yl)ketone 
• 569328-84-3 (5-chloro-3-methoxymethyl-2-nitrophenyl)(4,6-dimethoxypyrimidin-2-yl)acetonitrile 

Relevant academic research and scientific papers

Synthesis of novel quinazolinone derivatives with methyl (E)-2-(3-methoxy)acrylate moiety

A new series of quinazolinone derivatives with methyl (E)-2-(3-methoxy) acrylate moiety have been designed and synthesized. All target compounds had been identified by 1H NMR spectrum, IR spectrum and HR-MS (high resolution mass spectrum). Three target compounds (10a, 10e, 10h) were chosen to preliminarily test the antibacterial activities, the results showed that all three target compounds exhibited antibacterial activities against three bacterial strains (Proteobacteria, Salmonella, Colibacillus).

PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF

Provided is a process by which pyrimidinylacetonitrile derivatives can be prepared easily and efficiently from industrially available raw materials. Also provided are intermediates for the synthesis of the derivatives. A process for the preparation of pyr

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor

Systematic SAR studies of in vitro factor Xa inhibitory activity around compound 1 were performed by modifying each of the three phenyl rings. A class of highly potent, selective, efficacious and orally bioavailable direct factor Xa inhibitors was discovered. These compounds were screened in hERG binding assays to examine the effects of substitution groups on the hERG channel affinity. From the leading compounds, betrixaban (compound 11, PRT054021) has been selected as the clinical candidate for development.

INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1

This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD l in mammals.Formula (I).

Quaternary amidino based inhibitors of factor xa

Novel quaternary amidino-containing compounds of the general formulae (I), (II), (III), (IV), (V) and (VI): including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa

Aromatic nitro compounds containing diffusible groups cleavable by intramolecular nucleophilic displacement

Aromatic nitro compounds are disclosed where the aromatic ring contains electron-withdrawing groups and said aromatic nitro compound is capable of undergoing intramolecular nucleophilic displacement after reduction of the nitro group. The compounds are es